HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

32 citing papers in PubMed, 56 citations in OpenAlex.

1. Heat shock factor 1 promotes proliferation and chemoresistance in diffuse large B-cell lymphoma by enhancing the cell cycle and DNA repair.Cell death & disease · 2025
   Article
2. Causal Links Between Bone Diseases and Temporomandibular Disorders.International dental journal · 2025
   Article
3. Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma.Clinical and experimental medicine · 2025
   Review
4. NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
   Article
5. HSF1 Activation Mechanisms, Disease Roles, and Small Molecule Therapeutics.International journal of biological sciences · 2025
   Review
6. Heat shock factor 1 inhibition enhances the effects of modulated electro hyperthermia in a triple negative breast cancer mouse model.Scientific reports · 2024
   Article
7. Heat Shock Factor 1 Inhibition: A Novel Anti-Cancer Strategy with Promise for Precision Oncology.Cancers · 2023
   Review
8. Heat shock factor 1 (HSF1) specifically potentiates c-MYC-mediated transcription independently of the canonical heat shock response.Cell reports · 2023
   Article
9. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.Journal of medicinal chemistry · 2023
   Article
10. Dual inhibition of HSF1 and DYRK2 impedes cancer progression.Bioscience reports · 2023
    Article
11. HSF1 and Its Role in Huntington's Disease Pathology.Advances in experimental medicine and biology · 2023
    Review
12. Targeting HSF1 for cancer treatment: mechanisms and inhibitor development.Theranostics · 2023
    Review
13. Ovarian tumorB1-mediated heat shock transcription factor 1 deubiquitination is critical for glycolysis and development of endometriosis.iScience · 2022
    Article
14. Clinical significance and potential mechanism of heat shock factor 1 in acute myeloid leukemia.Aging · 2022
    Article
15. Is there a role for HSF1 in viral infections?FEBS open bio · 2022
    Review
16. HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5-WDR5-dependent transcriptional program.Cancer communications (London, England) · 2022
    Article
17. FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an mMolecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
18. Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy.Frontiers in cell and developmental biology · 2022
    Review
19. KRIBB11: A Promising Drug that Promotes Microglial Process Elongation and Suppresses Neuroinflammation.Frontiers in pharmacology · 2022
    Article
20. The Multifaceted Role of HSF1 in Pathophysiology: Focus on Its Interplay with TG2.International journal of molecular sciences · 2021
    Review

Corrections and comments

• Commented on by
  Targeting HSF1: A Prime Integrator of Proteotoxic Stress Response in Myeloma.2018

Authors and funding

17 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as